Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b Using Statistical Methods and Data Mining Techniques

Journal of Interferon and Cytokine Research

Volumn 36, Issue 5, 2016, Pages 338-346

  El Raziky, Maissa ^a   Fathalah, Waleed Fouad ^a   Zakaria, Zeinab ^a   Eldeen, Hadeel Gamal ^a   Abul Fotouh, Amr ^a   Salama, Ahmed ^a   Awad, Abubakr ^b   Esmat, Gamal ^a   Mabrouk, Mahasen ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b Cairo University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTHROMBIN; RIBAVIRIN; THYROTROPIN; ALPHA INTERFERON; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHRONIC HEPATITIS C; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EGYPTIAN; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LEUKOCYTE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SUSTAINED VIROLOGICAL RESPONSE; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; ADOLESCENT; COMPARATIVE STUDY; DATA MINING; EGYPT; HEPATITIS C, CHRONIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; DATA MINING; EGYPT; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84978112141     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2015.0141     Document Type: Article

References (32)

1. Abdo AA, Sanai FM. 2009. Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects. Ann Saudi Med 29(1):1-3.
2. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G. 2010. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 138(1):116-122.
3. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, Esmat G, Hamid MA, Mohamed MK, Fontanet A. 2006. Higher clearance of hepatitis C virus infection in females compared with males. Gut 55(8):1183-1187.
4. Baquerizo A, Anselmo D, Shackleton C, Chen TW, Cao C, Weaver M, Gornbein J, Geevarghese S, Nissen N, Farmer D, Demetriou A, Busuttil RW. 2003. Phosphorus as an early predictive factor in patients with acute liver failure. Transplantation 75:2007-2014.
5. Bedossa P, Poynard T.1996. An algorithm for grading activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293.
6. Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. 2006. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130(4): 1086-1097.
7. Breiman L, Friedman R, Olshen C, Stone C. 1980. Classification and regression trees. Belmont, CA: Wadsworth
8. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G. 2004. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 9:491-497.
9. Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakoob R, Al-Marri A, Amer AM, Morad N, Bener A. 2006. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 12(35):5692-5698.
10. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK. 2009. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 81(9):1576-1583.
11. Esmat G, El Raziky M, Elsharkawy A, Sabry D, Hassany M, Ahmed A, Assem N, El Kassas M, Doss W. 2015. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res 35(1): 49-54.
12. Foster GR. 2010. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 70(2):147-165.
13. Guerra J, Garenne M, Mohamed MK, Fontanet A. 2012. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 19(8):560-567.
14. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, Izumi N. 2010. A predictive model of response to peginterferon/ribavirinin chronic hepatitis C using classification and regression tree analysis. Hepatol Res 40:251-260.
15. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N. 2011a. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol 83(3):445-452.
16. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N. 2011b. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 46(3):401-409.
17. Mabrouk M, Doss W, Zayed N, Afify S, Esmat G. 2013. Impact of serum alpha-fetoprotein levels on the response to antiviral therapy in Egyptian patients with chronic hepatitis C. J Gastroenterol Hepatol Res 12(5):597-601.
18. Males S, Gad R, Esmat G, Abobakr H, Anwar M, Rekacewicz C, El Hoseiny M, Zalata K, Abdel-Hamid M, Bedossa P, Pol S, Mohamed MK, Fontanet A. 2007. Serum alphafoetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther 12(5):797-803.
19. Masood N, Ghori R, Memon A, Memon S, Memon KI, Memon I, Jaffri M, Baloch GH. 2008. Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection. J Coll Physicians Surg Pak 18(6):347-351.
20. Mehta M, Agrawal R and Rissanen J. 1996. SLIQ: A fast scalable classifier for data mining. In: Gardarin, G. ed. Proceedings of the 5th international conference on extending database technology: advances in database technology (EDBT'96). Berlin: Springer-Verlag, pp.18-32.
21. Nadeem A, Aslam M. 2012. Association of interferon-alpha and ribavirin-induced thyroid dysfunction with severity of disease and response to treatment in Pakistani Asian patients of chronic hepatitis C. Hepat Res Treat. 2012:864315, 6 pages.
22. Namiki I, Yasuhiro A, Masayuki K. 2010. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat 2010:703602.
23. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenquer Y. 2002. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97(9):2408-2414.
24. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. 2000. Combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31(1):211-218.
25. Ray SC, Arthur RR, Carella A, Bukh J Thomas DL. 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J Inf Dis 182:698-707.
26. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S. 2007. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357(2):124-134.
27. Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK. CHARIOT Study Group. 2011. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and rebavirin therapy in hepatitis c virus genotype 1. Hepatology 53(4): 1109-1117.
28. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG; IDEAL Study Team. 2010. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 139(5): 1602-1611.
29. Zayed N, Awad A, El-Akel W, Doss W, El-Raziky M, Mabrouk M. 2014. Low serum alpha-fetoprotein level an important predictor for therapeutic outcome in Egyptian patients with chronic hepatitis C: a data-mining analysis. J Gastrointest Dig Syst 4(6):240.
30. Zayed N, Awad AB, El-Akel W, Doss W, Awad T, Radwan A, Mabrouk M. 2013. The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 37:254-261.
31. Zechini B, Pasquazzi C, Aceti A. 2004. Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 16(9):891-896.
32. Zeuzem S, Buti M, Ferenci P, et al. 2006. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44(1):97-103.